Current Report Filing (8-k)
November 08 2012 - 5:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
Date of Report (Date of Earliest event Reported): November 8,
2012
CHINA BIOLOGIC PRODUCTS,
INC.
(Exact name of registrant as specified in its
charter)
Delaware
|
001-34566
|
75-2308816
|
(State or other jurisdiction of
|
(Commission File No.)
|
(IRS Employer ID No.)
|
incorporation or organization)
|
|
|
18th Floor, Jialong International Building
19
Chaoyang Park Road
Chaoyang District, Beijing 100125
Peoples Republic of China
(Address of Principal Executive
Offices)
86-10-6698-3166
Registrant's telephone number,
including area code
___________________________________________________________
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions (
see
General Instruction A.2. below):
[ ] Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On November 8, 2012, China Biologic Products, Inc. (the
Company) issued a press release announcing its financial results for its
fiscal quarter ended September 30, 2012. A copy of the press release, which the
Company is furnishing to the Securities and Exchange Commission, is attached as
Exhibit 99.1 and incorporated by reference herein.
The information contained in this Current Report on Form 8-K
and the exhibits attached hereto shall not be deemed to be filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange
Act), or otherwise subject to the liabilities of that section, nor shall such
information or such exhibits be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such a filing.
ITEM 7.01 REGULATION FD DISCLOSURE.
The information set forth in Item 2.02 above is incorporated by
reference herein.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: November 8, 2012
|
CHINA BIOLOGIC PRODUCTS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ David (Xiaoying)
Gao
|
|
|
David (Xiaoying) Gao
|
|
|
Chief Executive Officer
|
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024